MDA 2020 abstract: Demographic and safety data from patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) receiving ataluren in the STRIDE Registry
Our abstract presented at MDA 2020 outlines the demographic and safety data from the STRIDE observational drug registry of patients with nmDMD receiving a mutation-specific DMD therapy
A demographic analysis of the Strategic Targeting of Registries and International Database of Excellence (STRIDE) Registry population (data cut-off: 31 January 2019) and the principal interim safety results are presented
Read a concise overview of the objectives, approach, and interim safety analysis of this drug registry for patients with nmDMD
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.